Longeveron vs Cartesian Therapeutics
LGVN and RNAC side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How LGVN and RNAC compare
Cartesian Therapeutics is the larger company, worth 2.7 times as much as Longeveron ($184M against $67.3M).
Longeveron keeps more of each dollar of sales as profit, with a net margin of −1978% compared with −10284% at Cartesian Therapeutics.
Longeveron scores higher on the StockData Score (5 against 1 for Cartesian Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | LGVN | RNAC |
|---|---|---|
| Size and price | ||
| Market cap | $67.3M | $184M |
| Share price | $2.11 | $6.08 |
| Change, 1 year | −69.0% | −15.9% |
| Change, 5 years | −99.9% | −93.0% |
| Beta (5Y) | 1.44 | 2.27 |
| Employees | 37 | 75 |
| StockData Score | ||
| Total score | 5 (better) | 1 |
| Valuation score | 0 | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 5 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 56.7× (better) | 125× |
| P/B | 6.5× | – |
| FCF yield | −30.5% (better) | −42.7% |
| Growth | ||
| Revenue growth (TTM) | −42.7% | – |
| Revenue growth, 5Y average | −26.6% (better) | −30.0% |
| Profitability | ||
| Gross margin | 69.8% | – |
| Operating margin | −1993% (better) | −10519% |
| Net margin | −1978% (better) | −10284% |
| FCF margin | −1730% (better) | −5322% |
| Return on equity | −204% | – |
| Return on invested capital | −1412% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Current ratio | 2.63 | 7.48 (better) |
| Altman Z-score | −9.42 | −4.57 (better) |
| Piotroski F-score | 1 | 2 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 1.5% | 29.3% |
| Held by insiders | 43.8% | 55.7% |
| Insider net buying, 12 months | – | −$52.9K |
| Short interest, % of float | 0.88% | 14.3% |
Go deeper
- LGVN stock overview
- LGVN income statement
- LGVN valuation and score
- RNAC stock overview
- RNAC income statement
- RNAC valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.